At a glance
- Originator Pierrel
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 24 Dec 1997 No-Development-Reported for Hyperlipidaemia in Italy (Unknown route)
- 19 May 1995 Preclinical development for Hyperlipidaemia in Italy (Unknown route)